Anzeige
Mehr »
Login
Mittwoch, 12.03.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Warum diese Aktie jetzt die Chance auf +100 % Kurspotenzial hat!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CSAQ | ISIN: GB00BK80TJ35 | Ticker-Symbol: N/A
1-Jahres-Chart
PHYSITRACK PLC Chart 1 Jahr
5-Tage-Chart
PHYSITRACK PLC 5-Tage-Chart
ACCESS Newswire
187 Leser
Artikel bewerten:
(1)

Physitrack Plc Wins Finnish County Tender, Securing €63,000 Deal with Potential to Exceed €200,000

Finanznachrichten News

LONDON, UK / ACCESS Newswire / March 7, 2025 / Physitrack PLC (STO:PTRK) has successfully secured a public tender with a Finnish county healthcare system, reinforcing its position as a trusted provider in the region. The contract, valued at a minimum of €63,000, has the potential to exceed €200,000 depending on the components activated within the tender.

The agreement includes an annual recurring revenue for the Physitrack platform for exercise prescription and data analysis of €31,500 for two years (total €63,000), with additional authorised components such as electronic medical record (EMR) system integration and a potential custom app contributing to the overall value.

Henrik Molin, CEO & co-founder of Physitrack Plc, expressed enthusiasm about the win:

"We are delighted to have been awarded this tender, which is a testament to both the strength of our product and our team's dedication. Our experience and expertise in navigating public procurement processes continue to set us apart. As we solidify our reputation among major institutions across Europe and the UK, our growing presence in Finland plays a crucial role in these competitive tenders."

This latest success underscores Physitrack Plc's expanding footprint in the region and its ability to deliver scalable, high-quality solutions for public sector healthcare.

A Spotlight interview with CEO & co-founder Henrik Molin can be found here:

https://vimeo.com/1058340240/3e20f7377a

Enquiries regarding this announcement should be addressed to:

Henrik Molin, CEO and co-founder, Physitrack.
+44 208 133 9325
ir@physitrack.com
media@physitrack.com

About Physitrack

Physitrack PLC, founded in 2012, is a global digital healthcare provider, focused on the B2B wellness and virtual-first care markets. With staff with 12 nationalities on four continents, customers in 17 time zones, and end users in 187 countries, Physitrack is a truly global company.

The company has two business lines:
1. Lifecare - SaaS platform tailored mainly to physiotherapy and musculoskeletal care, enabling practitioners to deliver clinical home exercises, education prescription, outcomes tracking, triaging and Telehealth.
2. Wellness / Champion Health - SaaS platform for Employee Wellness and care powered by a combination of world-leading technology and wellness professionals based in the United Kingdom, Germany and the Nordics.

Physitrack PLC is headquartered in London, United Kingdom, and listed on Nasdaq First North Premier Growth Market (PTRK).

Visit us at
https://physitrackgroup.com/ (investor relations)
https://physitrack.com (product marketing)

About Champion Health

Champion Health, a subsidiary of Physitrack Plc, is a leader in corporate wellness technology, providing an innovative platform that empowers businesses to support their employees' well-being through personalised wellness action plans and advanced analytics.

Visit us at
https://championhealth.co.uk/

Attachments

Physitrack Plc Wins Finnish County Tender, Securing €63,000 Deal with Potential to Exceed €200,000

SOURCE: Physitrack PLC



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.